€100B
Opportunity over the next 10 years
50M+
People with epilepsy worldwide (WHO)
2
Products — Health Tracker live, Seizure Detector targeting 2027
Business model
Every cost becomes an asset
The problem with traditional pharma
Running a regulated pharmaceutical company requires a stack of expensive tools: clinical tracking systems, data platforms and compliance software. These are recurring costs — pure OPEX with no residual value.
How Medora does it differently
We build every tool we need in-house, then open it to other companies facing the same needs. What would be a subscription fee becomes a capital asset — built once, owned forever, and monetised continuously.
The result: our software portfolio generates recurring B2B revenue that directly funds R&D on our core medical mission — the seizure detector. Investors get exposure to both a medtech device company and a growing SaaS portfolio.